10-K: Cigna Group Details Share Structure and Governance in SEC Filing

The Cigna Group's recent 10-K filing outlines the company's capital structure, shareholder rights, and corporate governance practices.

Summary

• The Cigna Group has authorized 600 million shares of common stock and 25 million shares of preferred stock.
• Common stockholders are entitled to dividends when declared by the board and one vote per share.
• In the event of liquidation, common stockholders share in assets after debts and preferred stock liquidation preferences are satisfied.
• The board of directors can issue preferred stock with varying voting powers and preferences.
• The board must consist of 8 to 16 directors, elected by a majority vote, except in contested elections where a plurality vote is used.
• Directors can be removed with or without cause by a majority vote of outstanding capital stock.
• The company's bylaws can be amended by a majority vote of the capital stock or by the board of directors.
• Special stockholder meetings can be called by the board, CEO, or by shareholders owning at least 25% of voting power.
• Stockholder nominations and proposals must be received 90 to 120 days before the annual meeting.
• Proxy access allows stockholders owning 3% or more of common stock for at least three years to nominate directors.
• Cigna has opted out of Delaware's anti-takeover statute.
• The company's bylaws specify Delaware state courts as the exclusive forum for certain legal actions.
• Directors and officers have limited liability as permitted by Delaware law and are indemnified by the company.
• The company's 2023 10-K filing includes adjusted revenues of $195.3 billion and adjusted income from operations of $7.4 billion.
• Evernorth Health Services reported adjusted revenues of $153.5 billion and pre-tax adjusted income from operations of $6.4 billion.
• Cigna Healthcare reported adjusted revenues of $51.2 billion and pre-tax adjusted income from operations of $4.5 billion.
• Other Operations reported adjusted revenues of $0.6 billion and pre-tax adjusted income from operations of $96 million.
• The company has a global workforce of approximately 72,500 employees and serves over 164 million customer relationships.
• The company has two growth platforms: Evernorth Health Services and Cigna Healthcare.
• The company has a strategic corporate venture fund, The Cigna Group Ventures, with $700 million committed.
• The company has a minority ownership in VillageMD with a $2.7 billion investment.
• The company's capital expenditures for property, equipment and computer software were $1.6 billion in 2023.
• The company has over 400 United States patents.
• The company has a seven-year pharmacy program contract with the Department of Defense through 2029.
• The company has a multi-year agreement with Centene Corporation to manage pharmacy benefit services for approximately 20 million customers.
• The company has an agreement with Prime Therapeutics LLC to deliver improved choice and affordability for Prime's clients and their customers through 2025.
• The company entered into a definitive agreement to sell the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses to HCSC for $3.3 billion cash.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company shows strong revenue and growth in certain areas, the sale of the Medicare business and the associated loss, along with various risks and uncertainties, temper the overall sentiment. The company is also making strategic investments and has a strong market position, which are positive factors.

Positives

• The company has a strong financial position with significant adjusted revenues and income from operations.
• The company has a diverse portfolio of businesses with two growth platforms: Evernorth Health Services and Cigna Healthcare.
• The company is investing in innovation and technology to improve its services and customer experience.
• The company has a large global workforce and serves a significant number of customer relationships.
• The company has strategic partnerships and agreements with key players in the healthcare industry.
• The company has a strong intellectual property portfolio with over 400 patents.

Negatives

• The company is selling its Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses, which may impact future revenue.
• The company's Other Operations segment has relatively low adjusted revenues and pre-tax adjusted income from operations.
• The company's financial results are subject to various risks and uncertainties, including competition, regulatory changes, and economic conditions.

Risks

• The company's future performance depends on its ability to execute strategic and operational initiatives effectively.
• The company operates in a highly competitive and rapidly changing industry.
• The company faces price competition and other pressures that could compress margins.
• The company's reserves for expected medical claims are based on estimates that involve an extensive degree of judgment and are inherently variable.
• The company's business depends on its ability to maintain satisfactory relationships with health care providers and pharmaceutical manufacturers.
• The company's business depends on its ability to effectively invest in and maintain its information technology and other business systems.
• The company and its vendors are subject to cyberattacks or other privacy or data security incidents.
• The company's use of artificial intelligence and machine learning present regulatory and legal challenges.
• The company faces political, legal, operational, regulatory, economic and other risks that could affect its multinational operations.
• Strategic transactions involve risks and the company may not realize the expected benefits.
• The company is dependent on the success of its relationships with third parties.
• A significant disruption in service within the company's operations or among its key suppliers or other third parties could materially adversely affect its business and results of operations.
• The company may be subject to additional liability in connection with managing medical practices and operating pharmacies, onsite clinics and other types of medical facilities.
• The company's business is subject to substantial government regulation, as well as new laws or regulations or changes in existing laws or regulations.
• The company faces risks related to litigation, regulatory audits and investigations.
• The company is subject to the credit risk of its reinsurers.
• Unfavorable economic and market conditions may adversely affect the company's business, results of operations and financial condition.

Future Outlook

The company will continue to cultivate its portfolio of businesses to deliver foundational and accelerated growth and cross-enterprise leverage. The company will leverage its strong foundation and continue to capitalize on opportunities including: expanding its markets by evolving its service offerings to meet changing customer demands, including focusing on its Care Solutions businesses; increasing transparency and predictability; delivering on biosimilar opportunities; driving improved enterprise affordability initiatives value; investing in its business, infrastructure and people to drive enterprise growth; and continuing to build on its new relationship with Centene.

Management Comments

• At The Cigna Group, we relentlessly challenge ourselves to partner and innovate solutions for better health.
• Our global workforce of approximately 72,500 colleagues work to fulfill our mission to improve the health and vitality of over 164 million customer relationships in more than 30 markets and jurisdictions.
• We have two growth platforms: Evernorth Health Services and Cigna Healthcare.
• To transform the differentiated value we deliver to our customers, patients, clients, communities and investors into attractive, sustained growth, we continue to cultivate our portfolio of businesses with the goal of consistently delivering the foundational growth , accelerated growth and opportunity for cross-enterprise leverage we expect today and in the future.

Industry Context

The health care industry is undergoing substantial consolidation and is subject to significant market pressures. Many of the largest managed care organizations now also own health services businesses that compete with Evernorth Health Services. The company's focus on improving the health and vitality of those it serves will allow it to further differentiate itself from its primary competitors.

Comparison to Industry Standards

• The company's adjusted revenues of $195.3 billion are comparable to other large healthcare companies such as UnitedHealth Group (approximately $372 billion in 2023) and CVS Health (approximately $358 billion in 2023).
• The company's adjusted income from operations of $7.4 billion is also comparable to other large healthcare companies, but may vary based on business mix and strategic priorities.
• The company's medical care ratio of 81.3% is within the range of other large health insurers, but may vary based on the specific mix of business and geographic location.
• The company's adjusted expense ratio of 21.6% is also within the range of other large health insurers, but may vary based on the specific mix of business and strategic priorities.
• The company's focus on value-based care and integrated solutions is consistent with industry trends.
• The company's investment in digital health and technology is also consistent with industry trends.

Management Changes

Corporate Governance

Legal Proceedings

• The company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, and other legal matters arising in the ordinary course of business.
• The company is cooperating with subpoenas or similar processes from various governmental agencies requesting information.
• The company is involved in litigation with Elevance Health, Inc. regarding pricing and service issues, with a settlement reached on service-related claims, but Elevance has appealed the pricing-related claims.

Stakeholder Impact

• Shareholders: The company's financial performance and strategic decisions directly impact shareholder value.
• Employees: The company's human capital management practices and compensation programs affect employee well-being and engagement.
• Customers: The company's products and services impact the health and vitality of its customers.
• Suppliers: The company's relationships with suppliers affect their business and operations.
• Creditors: The company's financial condition and debt obligations impact its creditors.

Next Steps

• The company will continue to cultivate its portfolio of businesses to deliver foundational and accelerated growth and cross-enterprise leverage.
• The company will leverage its strong foundation and continue to capitalize on opportunities including: expanding its markets by evolving its service offerings to meet changing customer demands, including focusing on its Care Solutions businesses; increasing transparency and predictability; delivering on biosimilar opportunities; driving improved enterprise affordability initiatives value; investing in its business, infrastructure and people to drive enterprise growth; and continuing to build on its new relationship with Centene.
• The company expects to repurchase $5.0 billion of common stock in the first half of 2024.
• The company expects to complete the sale of the Medicare Advantage, Medicare Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits and CareAllies businesses to HCSC in the first quarter of 2025.

Key Dates

Keywords

healthcare, insurance, pharmacy, benefits, Evernorth, Cigna, Medicare, Medicaid, PBM, managed care, corporate governance, financial results, risk management, strategic investments, technology, digital health